{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:55:17Z","timestamp":1790769317152,"version":"4.1.0"},"publisher-location":"New York, NY","reference-count":109,"publisher":"Springer US","isbn-type":[{"value":"9781071654750","type":"print"},{"value":"9781071654767","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5476-7_2","type":"book-chapter","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:34:17Z","timestamp":1790764457000},"page":"19-51","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and Clinical Applications of Antisense Oligonucleotide Gapmers"],"prefix":"10.1007","author":[{"given":"Leanna","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiyza Akil","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pusti","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"6","key":"2_CR1","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.cell.2013.02.014","volume":"152","author":"TI Lee","year":"2013","unstructured":"Lee TI, Young RA (2013) Transcriptional regulation and its misregulation in disease. Cell 152(6):1237\u20131251. https:\/\/doi.org\/10.1016\/j.cell.2013.02.014","journal-title":"Cell"},{"issue":"2","key":"2_CR2","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1212\/NXG.0000000000000323","volume":"5","author":"DR Scoles","year":"2019","unstructured":"Scoles DR, Minikel EV, Pulst SM (2019) Antisense oligonucleotides. Neurol Genet 5(2):e323. https:\/\/doi.org\/10.1212\/NXG.0000000000000323","journal-title":"Neurol Genet"},{"issue":"1","key":"2_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","volume":"50","author":"CF Bennett","year":"2010","unstructured":"Bennett CF, Swayze EE (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50(1):259\u2013293. https:\/\/doi.org\/10.1146\/annurev.pharmtox.010909.105654","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"2_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","volume":"14","author":"C Rinaldi","year":"2017","unstructured":"Rinaldi C, Wood MJA (2017) Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol 14(1):9\u201321. https:\/\/doi.org\/10.1038\/nrneurol.2017.148","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"2_CR5","first-page":"347","volume":"1","author":"N Dias","year":"2002","unstructured":"Dias N, Stein CA (2002) Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 1(5):347\u2013355","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"2_CR6","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/S0021-9258(19)44152-5","volume":"248","author":"HI Miller","year":"1973","unstructured":"Miller HI, Riggs AD, Gill GN (1973) Ribonuclease H (hybrid) in Escherichia coli. Identification and characterization. J Biol Chem 248(7):2621\u20132624","journal-title":"J Biol Chem"},{"issue":"6","key":"2_CR7","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1111\/j.1742-4658.2009.06907.x","volume":"276","author":"T Tadokoro","year":"2009","unstructured":"Tadokoro T, Kanaya S (2009) Ribonuclease H: molecular diversities, substrate binding domains, and catalytic mechanism of the prokaryotic enzymes. FEBS J 276(6):1482\u20131493. https:\/\/doi.org\/10.1111\/j.1742-4658.2009.06907.x","journal-title":"FEBS J"},{"issue":"4","key":"2_CR8","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","volume":"46","author":"X Shen","year":"2018","unstructured":"Shen X, Corey DR (2018) Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res 46(4):1584\u20131600. https:\/\/doi.org\/10.1093\/nar\/gkx1239","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.31083\/ph.2016.5738","volume":"71","author":"A Grunweller","year":"2016","unstructured":"Grunweller A, Hartmann RK (2016) Chemical modification of nucleic acids as a key technology for the development of RNA-based therapeutics. Pharmazie 71(1):8\u201316","journal-title":"Pharmazie"},{"issue":"5-6","key":"2_CR10","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/j.1440-1681.2006.04403.x","volume":"33","author":"JHP Chan","year":"2006","unstructured":"Chan JHP, Lim S, Wong WSF (2006) Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 33(5-6):533\u2013540. https:\/\/doi.org\/10.1111\/j.1440-1681.2006.04403.x","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2018.1498390","volume":"37","author":"MVN Uppuladinne","year":"2018","unstructured":"Uppuladinne MVN, Sonavane UB, Deka RC et al. (2018) Structural insight into antisense gapmer-RNA oligomer duplexes through molecular dynamics simulations. J Biomol Struct Dyn 37:1\u201314. https:\/\/doi.org\/10.1080\/07391102.2018.1498390","journal-title":"J Biomol Struct Dyn"},{"issue":"12","key":"2_CR12","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/phar.1672","volume":"35","author":"RS Patel","year":"2015","unstructured":"Patel RS, Scopelliti EM, Savelloni J (2015) Therapeutic management of familial hypercholesterolemia: current and emerging drug therapies. Pharmacotherapy 35(12):1189\u20131203. https:\/\/doi.org\/10.1002\/phar.1672","journal-title":"Pharmacotherapy"},{"key":"2_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/978-981-13-2977-7_5","volume-title":"Human pathobiochemistry","author":"M-a Kawashiri","year":"2019","unstructured":"Kawashiri M-a, Rader DJ (2019) Familial hypercholesterolemia. In: Oohashi T, Tsukahara H, Ramirez F, Barber C, Otsuka F (Eds.) Human pathobiochemistry. Springer, Singapore, 43\u201356"},{"issue":"3","key":"2_CR14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/HCO.0000000000000385","volume":"32","author":"CS Bruikman","year":"2017","unstructured":"Bruikman CS, Hovingh GK, Kastelein JJ (2017) Molecular basis of familial hypercholesterolemia. Curr Opin Cardiol 32(3):262\u2013266. https:\/\/doi.org\/10.1097\/HCO.0000000000000385","journal-title":"Curr Opin Cardiol"},{"key":"2_CR15","unstructured":"Youngblom E, Pariani M, Knowles JW (1993) Familial hypercholesterolemia. In: Adam MP, Ardinger HH, Pagon RA et al (eds) GeneReviews((R)). Seattle (WA): University of Washington, Seattle."},{"key":"2_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/tacg.s8285","volume":"3","author":"I De Castro-Oros","year":"2010","unstructured":"De Castro-Oros I, Pocovi M, Civeira F (2010) The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations. Appl Clin Genet 3:53\u201364. https:\/\/doi.org\/10.2147\/tacg.s8285","journal-title":"Appl Clin Genet"},{"issue":"11","key":"2_CR17","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1111\/bph.13636","volume":"174","author":"A Santini","year":"2017","unstructured":"Santini A, Novellino E (2017) Nutraceuticals in hypercholesterolaemia: an overview. Br J Pharmacol 174(11):1450\u20131463. https:\/\/doi.org\/10.1111\/bph.13636","journal-title":"Br J Pharmacol"},{"issue":"8","key":"2_CR18","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/S0022-2275(20)42605-7","volume":"31","author":"TL Innerarity","year":"1990","unstructured":"Innerarity TL, Mahley RW, Weisgraber KH et al. (1990) Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 31(8):1337\u20131349","journal-title":"J Lipid Res"},{"key":"2_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/TACG.S44315","volume":"8","author":"A Vogt","year":"2015","unstructured":"Vogt A (2015) The genetics of familial hypercholesterolemia and emerging therapies. Appl Clin Genet 8:27. https:\/\/doi.org\/10.2147\/TACG.S44315","journal-title":"Appl Clin Genet"},{"issue":"2","key":"2_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jacl.2014.11.011","volume":"9","author":"CH Huang","year":"2015","unstructured":"Huang CH, Chiu PC, Liu HC et al. (2015) Clinical observations and treatment of pediatric homozygous familial hypercholesterolemia due to a low-density lipoprotein receptor defect. J Clin Lipidol 9(2):234\u2013240. https:\/\/doi.org\/10.1016\/j.jacl.2014.11.011","journal-title":"J Clin Lipidol"},{"issue":"9719","key":"2_CR21","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","volume":"375","author":"FJ Raal","year":"2010","unstructured":"Raal FJ, Santos RD, Blom DJ et al. (2010) Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. The Lancet 375(9719):998\u20131006. https:\/\/doi.org\/10.1016\/S0140-6736(10)60284-X","journal-title":"The Lancet"},{"issue":"5","key":"2_CR22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40265-013-0042-2","volume":"73","author":"P Hair","year":"2013","unstructured":"Hair P, Cameron F, McKeage K (2013) Mipomersen sodium: first global approval. Drugs 73(5):487\u2013493. https:\/\/doi.org\/10.1007\/s40265-013-0042-2","journal-title":"Drugs"},{"issue":"2","key":"2_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.18553\/jmcp.2013.19.2.139","volume":"19","author":"JG Robinson","year":"2013","unstructured":"Robinson JG (2013) Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Manag Care Pharm 19(2):139\u2013149. https:\/\/doi.org\/10.18553\/jmcp.2013.19.2.139","journal-title":"J Manag Care Pharm"},{"issue":"19","key":"2_CR24","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1161\/CIRCULATIONAHA.112.104125","volume":"126","author":"EA Stein","year":"2012","unstructured":"Stein EA, Dufour R, Gagne C et al. (2012) Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 126(19):2283\u20132292","journal-title":"Circulation"},{"issue":"2","key":"2_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/14656566.2018.155007","volume":"20","author":"JS Parham","year":"2019","unstructured":"Parham JS, Goldberg AC (2019) Mipomersen and its use in familial hypercholesterolemia. Expert Opin Pharmacother 20(2):127\u2013131. https:\/\/doi.org\/10.1080\/14656566.2018.155007","journal-title":"Expert Opin Pharmacother"},{"key":"2_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/VHRM.S191965","volume":"18","author":"D Chambergo-Michilot","year":"2022","unstructured":"Chambergo-Michilot D, Alur A, Kulkarni S, Agarwala A (2022) Mipomersen in familial hypercholesterolemia: an update on health-related quality of life and patient-reported outcomes. Vasc Health Risk Manag 18:73\u201380. https:\/\/doi.org\/10.2147\/VHRM.S191965","journal-title":"Vasc Health Risk Manag"},{"issue":"7","key":"2_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jns.12153","volume":"23","author":"M Gertz","year":"2016","unstructured":"Gertz M (2016) Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. J Peripher Nerv Syst 23(7):5\u20139. https:\/\/doi.org\/10.1111\/jns.12153","journal-title":"J Peripher Nerv Syst"},{"issue":"13","key":"2_CR28","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","volume":"78","author":"SJ Keam","year":"2018","unstructured":"Keam SJ (2018) Inotersen: first global approval. Drugs 78(13):1371\u20131376. https:\/\/doi.org\/10.1007\/s40265-018-0968-5","journal-title":"Drugs"},{"issue":"2","key":"2_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/joim.12506","volume":"280","author":"M Ankarcrona","year":"2016","unstructured":"Ankarcrona M, Winblad B, Monteiro C et al. (2016) Current and future treatment of amyloid diseases. J Intern Med 280(2):177\u2013202. https:\/\/doi.org\/10.1111\/joim.12506","journal-title":"J Intern Med"},{"issue":"3","key":"2_CR30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/jcpt.12145","volume":"39","author":"Y Sekijima","year":"2014","unstructured":"Sekijima Y (2014) Recent progress in the understanding and treatment of transthyretin amyloidosis. J Clin Pharm Ther 39(3):225\u2013233. https:\/\/doi.org\/10.1111\/jcpt.12145","journal-title":"J Clin Pharm Ther"},{"key":"2_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17512433.2019.1635008","volume":"12","author":"MA Gertz","year":"2019","unstructured":"Gertz MA, Scheinberg M, Waddington-Cruz M et al. (2019) Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. Expert Rev Clin Pharmacol 12:1\u201311. https:\/\/doi.org\/10.1080\/17512433.2019.1635008","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2_CR32","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2147\/DDDT.S162913","volume":"13","author":"V Mathew","year":"2019","unstructured":"Mathew V, Wang AK (2019) Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis. Drug Des Devel Ther 13:1515\u20131525. https:\/\/doi.org\/10.2147\/DDDT.S162913","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"2_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL et al. (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379(1):22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1716793","journal-title":"N Engl J Med"},{"key":"2_CR34","doi-asserted-by":"publisher","first-page":"6416","DOI":"10.1007\/s00415-022-11276-8","volume":"269","author":"TH Brannagan","year":"2022","unstructured":"Brannagan TH, Coelho T, Wang AK et al. (2022) Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update. J Neurol 269:6416\u20136427. https:\/\/doi.org\/10.1007\/s00415-022-11276-8","journal-title":"J Neurol"},{"issue":"15","key":"2_CR35","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","volume":"330","author":"T Coelho","year":"2023","unstructured":"Coelho T, Marques W, Dasgupta NR et al. (2023) Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA 330(15):1448\u20131458. https:\/\/doi.org\/10.1001\/jama.2023.18688","journal-title":"JAMA"},{"issue":"4","key":"2_CR36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.tibs.2016.01.003","volume":"41","author":"SK Calderwood","year":"2016","unstructured":"Calderwood SK, Gong J (2016) Heat shock proteins promote cancer: it\u2019s a protection racket. Trends Biochem Sci 41(4):311\u2013323. https:\/\/doi.org\/10.1016\/j.tibs.2016.01.003","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"2_CR37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3892\/ijo.2014.2399","volume":"45","author":"X Wang","year":"2014","unstructured":"Wang X, Chen M, Zhou J et al. (2014) HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy (review).  Int J Oncol 45(1):18\u201330. https:\/\/doi.org\/10.3892\/ijo.2014.2399","journal-title":"Int J Oncol"},{"issue":"24","key":"2_CR38","doi-asserted-by":"publisher","first-page":"11779","DOI":"10.1158\/0008-5472.CAN-07-2441","volume":"67","author":"C O\u2019Callaghan-Sunol","year":"2007","unstructured":"O\u2019Callaghan-Sunol C, Gabai VL, Sherman MY (2007) Hsp27 modulates p53 signaling and suppresses cellular senescence. Cancer Res 67(24):11779\u201311788. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-2441","journal-title":"Cancer Res"},{"issue":"10","key":"2_CR39","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1158\/0008-5472.CAN-12-3979","volume":"73","author":"M Shiota","year":"2013","unstructured":"Shiota M, Bishop JL, Nip KM et al. (2013) Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Res 73(10):3109\u20133119. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-3979","journal-title":"Cancer Res"},{"issue":"21","key":"2_CR40","doi-asserted-by":"publisher","first-page":"10455","DOI":"10.1158\/0008-5472.CAN-07-2057","volume":"67","author":"A Zoubeidi","year":"2007","unstructured":"Zoubeidi A, Zardan A, Beraldi E et al. (2007) Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 67(21):10455\u201310465. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-2057","journal-title":"Cancer Res"},{"issue":"2","key":"2_CR41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/14656566.2018.1548611","volume":"20","author":"AE Dellis","year":"2019","unstructured":"Dellis AE, Papatsoris AG (2019) Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer. Expert Opin Pharmacother 20(2):163\u2013172. https:\/\/doi.org\/10.1080\/14656566.2018.1548611","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"2_CR42","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1093\/annonc\/mdw068","volume":"27","author":"KN Chi","year":"2016","unstructured":"Chi KN, Yu EY, Jacobs C et al. (2016) A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers. Ann Oncol 27(6):1116\u20131122. https:\/\/doi.org\/10.1093\/annonc\/mdw068","journal-title":"Ann Oncol"},{"issue":"2","key":"2_CR43","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s10637-017-0553-x","volume":"36","author":"EY Yu","year":"2018","unstructured":"Yu EY, Ellard SL, Hotte SJ et al. (2018) A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer. Invest New Drugs 36(2):278\u2013287. https:\/\/doi.org\/10.1007\/s10637-017-0553-x","journal-title":"Invest New Drugs"},{"issue":"11","key":"2_CR44","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/s41416-018-0087-9","volume":"118","author":"JE Rosenberg","year":"2018","unstructured":"Rosenberg JE, Hahn NM, Regan MM et al. (2018) Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). Br J Cancer 118(11):1434\u20131441. https:\/\/doi.org\/10.1038\/s41416-018-0087-9","journal-title":"Br J Cancer"},{"issue":"12","key":"2_CR45","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1634\/theoncologist.2017-0066","volume":"22","author":"AH Ko","year":"2017","unstructured":"Ko AH, Murphy PB, Peyton JD et al. (2017) A Randomized, double-blinded, phase II trial of gemcitabine and nab-paclitaxel plus apatorsen or placebo in patients with metastatic pancreatic cancer: the RAINIER trial. Oncologist 22(12):1427\u2013e1129. https:\/\/doi.org\/10.1634\/theoncologist.2017-0066","journal-title":"Oncologist"},{"issue":"2","key":"2_CR46","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.tcm.2019.03.001","volume":"30","author":"V Chyzhyk","year":"2019","unstructured":"Chyzhyk V, Brown AS (2019) Familial chylomicronemia syndrome: a rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis. Trends Cardiovasc Med 30(2):80\u201385. https:\/\/doi.org\/10.1016\/j.tcm.2019.03.001","journal-title":"Trends Cardiovasc Med"},{"issue":"23","key":"2_CR47","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","volume":"371","author":"D Gaudet","year":"2014","unstructured":"Gaudet D, Brisson D, Tremblay K et al. (2014) Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med 371(23):2200\u20132206. https:\/\/doi.org\/10.1056\/NEJMoa1400284","journal-title":"N Engl J Med"},{"key":"2_CR48","doi-asserted-by":"publisher","unstructured":"Paik J, Duggan S (2019) Volanesorsen: first global approval. Drugs. https:\/\/doi.org\/10.1007\/s40265-019-01168-z","DOI":"10.1007\/s40265-019-01168-z"},{"key":"2_CR49","unstructured":"National Library of Medicine (US). LPL gene. MedlinePlus Genetics. Available at: https:\/\/medlineplus.gov\/genetics\/gene\/lpl\/. Accessed June 27, 2026."},{"issue":"6","key":"2_CR50","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nrendo.2015.26","volume":"11","author":"AJ Brahm","year":"2015","unstructured":"Brahm AJ, Hegele RA (2015) Chylomicronaemia\u2014current diagnosis and future therapies. Nat Rev Endocrinol 11(6):352\u2013362. https:\/\/doi.org\/10.1038\/nrendo.2015.26","journal-title":"Nat Rev Endocrinol"},{"key":"2_CR51","unstructured":"National Library of Medicine (US). Familial partial lipodystrophy. MedlinePlus Genetics. Available at: https:\/\/medlineplus.gov\/genetics\/condition\/familial-partial-lipodystrophy\/. Accessed 27 Jun 2026."},{"issue":"2","key":"2_CR52","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/ejhg.2016.102","volume":"25","author":"I J\u00e9ru","year":"2017","unstructured":"J\u00e9ru I, Vatier C, Araujo-Vilar D et al. (2017) Clinical utility gene card for: familial partial lipodystrophy. Eur J Hum Genet 25(2):271\u2013271. https:\/\/doi.org\/10.1038\/ejhg.2016.102","journal-title":"Eur J Hum Genet"},{"issue":"11","key":"2_CR53","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1136\/jcp.2008.055756","volume":"61","author":"G Ferns","year":"2008","unstructured":"Ferns G, Keti V, Griffin B (2008) Investigation and management of hypertriglyceridaemia. J Clin Pathol 61(11):1174\u20131183. https:\/\/doi.org\/10.1136\/jcp.2008.055756","journal-title":"J Clin Pathol"},{"issue":"8","key":"2_CR54","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","volume":"2","author":"RA Hegele","year":"2014","unstructured":"Hegele RA, Ginsberg HN, Chapman MJ et al. (2014) The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2(8):655\u2013666. https:\/\/doi.org\/10.1016\/S2213-8587(13)70191-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2_CR55","unstructured":"Akcea Therapeutics I (2018) FDA Advisory Committee votes in favor of WAYLIVRA for treatment of familial chylomicronemia syndrome. https:\/\/ir.akceatx.com\/news-releases\/news-release-details\/fda-advisory-committee-votes-favor-waylivra-treatment-familial. Accessed 27 Oct 2019"},{"key":"2_CR56","unstructured":"Akcea Therapeutics I (2018) Akcea and Ionis receive complete response letter for WAYLIVRA from FDA. https:\/\/ir.akceatx.com\/news-releases\/news-release-details\/akcea-and-ionis-receive-complete-response-letter-waylivra-fda. Accessed 29 Oct 2019"},{"key":"2_CR57","unstructured":"Government of Canada HC (2014) Search Page - Drug and Health Product Register. https:\/\/hpr-rps.hres.ca\/reg-content\/regulatory-decision-summary-detail.php?lang=en&linkID=RDS00490"},{"issue":"4","key":"2_CR58","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.jacl.2018.03.093","volume":"12","author":"RA Hegele","year":"2018","unstructured":"Hegele RA, Berberich AJ, Ban MR et al. (2018) Clinical and biochemical features of different molecular etiologies of familial chylomicronemia. J Clin Lipidol 12(4):920\u2013927 e924. https:\/\/doi.org\/10.1016\/j.jacl.2018.03.093","journal-title":"J Clin Lipidol"},{"issue":"3","key":"2_CR59","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jacl.2017.04.071","volume":"11","author":"D Gaudet","year":"2017","unstructured":"Gaudet D, Digenio A, Alexander VJ et al. (2017) The APPROACH study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS). J Clin Lipidol 11(3):814\u2013815. https:\/\/doi.org\/10.1016\/j.jacl.2017.04.071","journal-title":"J Clin Lipidol"},{"issue":"3","key":"2_CR60","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jacl.2023.04.007","volume":"17","author":"TA Prohaska","year":"2023","unstructured":"Prohaska TA et al. (2023) APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia. J\u00a0Clin Lipidol 17(3):406\u2013411","journal-title":"J Clin Lipidol"},{"key":"2_CR61","doi-asserted-by":"publisher","first-page":"119114","DOI":"10.1016\/j.atherosclerosis.2025.119114","volume":"403","author":"EA Brinton","year":"2025","unstructured":"Brinton EA et al. (2025) Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA. Atherosclerosis 403:119114","journal-title":"Atherosclerosis"},{"issue":"19","key":"2_CR62","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","volume":"390","author":"ESG Stroes","year":"2024","unstructured":"Stroes ESG et al. (2024) Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N Engl J Med 390(19):1781\u20131792","journal-title":"N Engl J Med"},{"key":"2_CR63","unstructured":"Tryngolza. (2025). Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tryngolza-epar-product-information_en.pdf. Accessed June 26, 2026"},{"key":"2_CR64","unstructured":"FDA (2026)\u00a0FDA Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia. www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-treatment-shown-reduce-risk-acute-pancreatitis-adults-severe-hypertriglyceridemia. Accessed July 5, 2026."},{"key":"2_CR65","unstructured":"Caron NS, Wright GEB, Hayden MR (1993) huntington disease. In: Adam MP, Ardinger HH, Pagon RA et al (eds) GeneReviews((R)). Seattle (WA): University of Washington, Seattle"},{"issue":"6","key":"2_CR66","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.3174\/ajnr.A3772","volume":"35","author":"S Mahalingam","year":"2014","unstructured":"Mahalingam S, Levy LM (2014) Genetics of huntington disease. AJNR Am J Neuroradiol 35(6):1070\u20131072. https:\/\/doi.org\/10.3174\/ajnr.A3772","journal-title":"AJNR Am J Neuroradiol"},{"issue":"7","key":"2_CR67","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a024240","volume":"7","author":"M Jimenez-Sanchez","year":"2017","unstructured":"Jimenez-Sanchez M, Licitra F, Underwood BR et al. (2017) Huntington\u2019s disease: mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb Perspect Med 7(7):a024240. https:\/\/doi.org\/10.1101\/cshperspect.a024240","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2_CR68","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2147\/DNND.S163808","volume":"9","author":"WF Kaemmerer","year":"2019","unstructured":"Kaemmerer WF, Grondin RC (2019) The effects of huntingtin-lowering: what do we know so far?. Degener Neurol Neuromuscul Dis 9:3\u201317. https:\/\/doi.org\/10.2147\/DNND.S163808","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"6","key":"2_CR69","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/jgm.361","volume":"5","author":"SJ Errington","year":"2003","unstructured":"Errington SJ, Mann CJ, Fletcher S et al. (2003) Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene. J Gene Med 5(6):518\u2013527","journal-title":"J Gene Med"},{"issue":"1","key":"2_CR70","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cell.2004.06.018","volume":"118","author":"LR Gauthier","year":"2004","unstructured":"Gauthier LR, Charrin BC, Borrell-Pages M et al. (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118(1):127\u2013138. https:\/\/doi.org\/10.1016\/j.cell.2004.06.018","journal-title":"Cell"},{"key":"2_CR71","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1750-1326-5-22","volume":"5","author":"B Ma","year":"2010","unstructured":"Ma B, Culver BP, Baj G et al. (2010) Localization of BDNF mRNA with the Huntington\u2019s disease protein in rat brain. Mol Neurodegener 5:22. https:\/\/doi.org\/10.1186\/1750-1326-5-22","journal-title":"Mol Neurodegener"},{"issue":"17","key":"2_CR72","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1523\/JNEUROSCI.3920-03.2004","volume":"24","author":"ZC Baquet","year":"2004","unstructured":"Baquet ZC, Gorski JA, Jones KR (2004) Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci 24(17):4250\u20134258. https:\/\/doi.org\/10.1523\/JNEUROSCI.3920-03.2004","journal-title":"J Neurosci"},{"issue":"1","key":"2_CR73","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1471-4159.2008.05734.x","volume":"108","author":"Y Zhang","year":"2009","unstructured":"Zhang Y, Engelman J, Friedlander RM (2009) Allele-specific silencing of mutant Huntington\u2019s disease gene. J Neurochem 108(1):82\u201390. https:\/\/doi.org\/10.1111\/j.1471-4159.2008.05734.x","journal-title":"J Neurochem"},{"issue":"10","key":"2_CR74","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","volume":"16","author":"EJ Wild","year":"2017","unstructured":"Wild EJ, Tabrizi SJ (2017) Therapies targeting DNA and RNA in Huntington\u2019s disease. Lancet Neurol 16(10):837\u2013847. https:\/\/doi.org\/10.1016\/S1474-4422(17)30280-6","journal-title":"Lancet Neurol"},{"key":"2_CR75","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","volume":"380","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi SJ, Leavitt BR, Landwehrmeyer GB et al. (2019) Targeting Huntingtin expression in patients with Huntington\u2019s disease. N Engl J Med 380:2307\u20132316. https:\/\/doi.org\/10.1056\/NEJMoa1900907","journal-title":"N Engl J Med"},{"issue":"1","key":"2_CR76","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3233\/JHD-189001","volume":"7","author":"FB Rodrigues","year":"2018","unstructured":"Rodrigues FB, Wild EJ (2018) Huntington\u2019s disease clinical trials corner: February 2018. J Huntingtons Dis 7(1):89\u201398. https:\/\/doi.org\/10.3233\/JHD-189001","journal-title":"J Huntingtons Dis"},{"key":"2_CR77","unstructured":"Ionis Pharmaceuticals I (2017) Ionis Pharmaceuticals Licenses IONIS-HTT Rx to partner following successful phase 1\/2a study in patients with Huntington\u2019s disease. https:\/\/ir.ionispharma.com\/news-releases\/news-release-details\/ionis-pharmaceuticals-licenses-ionis-htt-rx-partnerfollowing. Accessed June 26, 2026"},{"issue":"11","key":"2_CR78","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/mt.2015.128","volume":"23","author":"C Kay","year":"2015","unstructured":"Kay C, Collins JA, Skotte NH et al. (2015) Huntingtin haplotypes provide prioritized target panels for allele-specific silencing in Huntington disease patients of European ancestry. Mol Ther 23(11):1759\u20131771. https:\/\/doi.org\/10.1038\/mt.2015.128","journal-title":"Mol Ther"},{"key":"2_CR79","unstructured":"Wave Life Sciences provides update on phase 1B\/2A precision-HD trials (2021) https:\/\/ir.wavelifesciences.com\/news-releases\/news-release-details\/wave-life-sciences-provides-update-phase-1b2a-precision-hd"},{"issue":"11","key":"2_CR80","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.1073\/pnas.1117019109","volume":"109","author":"JE Lee","year":"2012","unstructured":"Lee JE, Bennett CF, Cooper TA (2012) RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1. Proc Natl Acad Sci 109(11):4221\u20134226. https:\/\/doi.org\/10.1073\/pnas.1117019109","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"2_CR81","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/0092-8674(92)90154-5","volume":"68","author":"JD Brook","year":"1992","unstructured":"Brook JD, McCurrach ME, Harley HG et al. (1992) Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell 68(4):799\u2013808. https:\/\/doi.org\/10.1016\/0092-8674(92)90154-5","journal-title":"Cell"},{"issue":"6","key":"2_CR82","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1042\/BST0371281","volume":"37","author":"E Lee Johanna","year":"2009","unstructured":"Lee Johanna E, Cooper Thomas A (2009) Pathogenic mechanisms of myotonic dystrophy. Biochm Soc Trans 37(6):1281\u20131286. https:\/\/doi.org\/10.1042\/BST0371281","journal-title":"Biochm Soc Trans"},{"key":"2_CR83","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.gde.2017.03.007","volume":"44","author":"CA Thornton","year":"2017","unstructured":"Thornton CA, Wang E, Carrell E (2017) Myotonic dystrophy: approach to therapy. Curr Opin Genet Dev 44:135\u2013140. https:\/\/doi.org\/10.1016\/j.gde.2017.03.007","journal-title":"Curr Opin Genet Dev"},{"issue":"5","key":"2_CR84","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1086\/383590","volume":"74","author":"LPW Ranum","year":"2004","unstructured":"Ranum LPW, Day JW (2004) Myotonic dystrophy: RNA pathogenesis comes into focus. Am J Hum Genet 74(5):793\u2013804. https:\/\/doi.org\/10.1086\/383590","journal-title":"Am J Hum Genet"},{"issue":"3","key":"2_CR85","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.ncl.2014.04.011","volume":"32","author":"CA Thornton","year":"2014","unstructured":"Thornton CA (2014) Myotonic dystrophy. Neurol Clin 32(3):705\u2013719. https:\/\/doi.org\/10.1016\/j.ncl.2014.04.011","journal-title":"Neurol Clin"},{"key":"2_CR86","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.omtn.2017.05.007","volume":"7","author":"D Jauvin","year":"2017","unstructured":"Jauvin D, Chr\u00e9tien J, Pandey SK et al. (2017) Targeting DMPK with antisense oligonucleotide improves muscle strength in myotonic dystrophy type 1 Mice. Mol Ther Nucleic Acids 7:465\u2013474. https:\/\/doi.org\/10.1016\/j.omtn.2017.05.007","journal-title":"Mol Ther Nucleic Acids"},{"issue":"16","key":"2_CR87","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.131175","volume":"4","author":"GJ Raymond","year":"2019","unstructured":"Raymond GJ, Zhao HT, Race B et al. (2019) Antisense oligonucleotides extend survival of prion-infected mice. JCI Insight 4(16):e131175. https:\/\/doi.org\/10.1172\/jci.insight.131175","journal-title":"JCI Insight"},{"issue":"1","key":"2_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1743-422X-8-559","volume":"8","author":"M Imran","year":"2011","unstructured":"Imran M, Mahmood S (2011) An overview of human prion diseases. Virol J 8(1):1\u20139. https:\/\/doi.org\/10.1186\/1743-422X-8-559","journal-title":"Virol J"},{"issue":"1","key":"2_CR89","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/19336896.2015.1110293","volume":"10","author":"CJ Atkinson","year":"2016","unstructured":"Atkinson CJ, Zhang K, Munn AL et al. (2016) Prion protein scrapie and the normal cellular prion protein. Prion 10(1):63\u201382. https:\/\/doi.org\/10.1080\/19336896.2015.1110293","journal-title":"Prion"},{"issue":"5646","key":"2_CR90","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1126\/science.1090187","volume":"302","author":"G Mallucci","year":"2003","unstructured":"Mallucci G, Dickinson A, Linehan J et al. (2003) Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302(5646):871\u2013874. https:\/\/doi.org\/10.1126\/science.1090187","journal-title":"Science"},{"issue":"29","key":"2_CR91","doi-asserted-by":"publisher","first-page":"10238","DOI":"10.1073\/pnas.0802759105","volume":"105","author":"MD White","year":"2008","unstructured":"White MD, Farmer M, Mirabile I et al. (2008) Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. PNAS 105(29):10238\u201310243. https:\/\/doi.org\/10.1073\/pnas.0802759105","journal-title":"PNAS"},{"issue":"2","key":"2_CR92","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1038\/mtna.2011.6","volume":"1","author":"K Nazor Friberg","year":"2012","unstructured":"Nazor Friberg K, Hung G, Wancewicz E et al. (2012) Intracerebral infusion of antisense oligonucleotides into prion-infected mice. Mol Ther Nucleic Acids 1(2):e9. https:\/\/doi.org\/10.1038\/mtna.2011.6","journal-title":"Mol Ther Nucleic Acids"},{"issue":"2","key":"2_CR93","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJMra1603471","volume":"377","author":"RH Brown","year":"2017","unstructured":"Brown RH, Al-Chalabi A (2017) Amyotrophic lateral sclerosis. N Engl J Med 377(2):162\u2013172","journal-title":"N Engl J Med"},{"issue":"4","key":"2_CR94","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ncl.2015.07.012","volume":"33","author":"S Saberi","year":"2025","unstructured":"Saberi S, Stauffer JE, Schulte DJ, Ravits J (2025) Neuropathology of amyotrophic lateral sclerosis and its variants. Neurol Clin 33(4):855\u2013876","journal-title":"Neurol Clin"},{"key":"2_CR95","first-page":"181","volume":"7","author":"C Ingre","year":"2015","unstructured":"Ingre C, Roos PM, Piehl F, Kamel F, Fang F (2015) Risk factors for amyotrophic lateral sclerosis. Clin Epidemiol 7:181\u2013193","journal-title":"Clin Epidemiol"},{"issue":"1","key":"2_CR96","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/bmb\/ldw026","volume":"119","author":"S Morgan","year":"2016","unstructured":"Morgan S, Orrell RW (2016) Pathogenesis of amyotrophic lateral sclerosis. Br Med Bull 119(1):87\u201398","journal-title":"Br Med Bull"},{"issue":"5","key":"2_CR97","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1212\/CON.0000000000000911","volume":"26","author":"C Quinn","year":"2020","unstructured":"Quinn C, Elman L (2020) Amyotrophic lateral sclerosis and other motor neuron diseases. Continuum (Minneap Minn) 26(5):1323\u20131347","journal-title":"Continuum (Minneap Minn)"},{"issue":"11","key":"2_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/cells12111523","volume":"12","author":"L Tzeplaeff","year":"2023","unstructured":"Tzeplaeff L, Wilfling S, Requardt MV, Herdick M (2023) Current state and future directions in the therapy of ALS. Cells 12(11):1523","journal-title":"Cells"},{"key":"2_CR99","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40265-023-01904-6","volume":"83","author":"HA Blair","year":"2023","unstructured":"Blair HA (2023) Tofersen: first approval. Drugs 83:1039\u20131043. https:\/\/doi.org\/10.1007\/s40265-023-01904-6","journal-title":"Drugs"},{"issue":"12","key":"2_CR100","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.tips.2023.08.008","volume":"44","author":"J Jin","year":"2023","unstructured":"Jin J, Zhong X (2023) ASO drug Qalsody (tofersen) targets amyotrophic lateral sclerosis. Trends Pharmacol Sci 44(12):1043\u20131044","journal-title":"Trends Pharmacol Sci"},{"key":"2_CR101","unstructured":"Biogen (2024) https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-receives-europeancommission-approval-qalsodyr-tofersen\/p"},{"issue":"12","key":"2_CR102","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller TM et al. (2022) Trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med 387(12):1099\u20131110. https:\/\/doi.org\/10.1056\/NEJMoa2204705","journal-title":"N Engl J Med"},{"key":"2_CR103","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.omtn.2017.11.004","volume":"10","author":"A Dieckmann","year":"2018","unstructured":"Dieckmann A, Hagedorn PH, Burki Y et al. (2018) A Sensitive in vitro approach to assess the hybridization-dependent toxic potential of high affinity gapmer oligonucleotides. Mol Ther Nucleic Acids 10:45\u201354. https:\/\/doi.org\/10.1016\/j.omtn.2017.11.004","journal-title":"Mol Ther Nucleic Acids"},{"issue":"6","key":"2_CR104","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41587-019-0106-2","volume":"37","author":"W Shen","year":"2019","unstructured":"Shen W, De Hoyos CL, Migawa MT et al. (2019) Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nat Biotechnol 37(6):640\u2013650. https:\/\/doi.org\/10.1038\/s41587-019-0106-2","journal-title":"Nat Biotechnol"},{"issue":"7","key":"2_CR105","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1021\/acs.bioconjchem.9b00385","volume":"30","author":"S Mignani","year":"2019","unstructured":"Mignani S, Shi X, Zablocka M et al. (2019) Dendrimer-enabled therapeutic antisense delivery systems as innovation in medicine. Bioconjugate Chem 30(7):1938\u20131950. https:\/\/doi.org\/10.1021\/acs.bioconjchem.9b00385","journal-title":"Bioconjugate Chem"},{"issue":"11","key":"2_CR106","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1016\/S0735-1097(18)32265-4","volume":"71","author":"VJ Alexander","year":"2018","unstructured":"Alexander VJ, Digenio A, Xia ST et al. (2018) Inhibition of apolipoprotein C-III with Galnac conjugated antisense drug potently lowers fasting serum apolipoprotein C-III and triglyceride levels in healthy volunteers with elevated triglycerides. J Am Coll Cardiol 71(11):1724\u20131724. https:\/\/doi.org\/10.1016\/S0735-1097(18)32265-4","journal-title":"J Am Coll Cardiol"},{"issue":"1-2","key":"2_CR107","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jim.2007.06.009","volume":"325","author":"NB Marshall","year":"2007","unstructured":"Marshall NB, Oda SK, London CA et al. (2007) Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing. J Immunol Methods 325(1-2):114\u2013126. https:\/\/doi.org\/10.1016\/j.jim.2007.06.009","journal-title":"J Immunol Methods"},{"issue":"10","key":"2_CR108","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1023\/a:1016260110049","volume":"12","author":"I Walker","year":"1995","unstructured":"Walker I, Irwin WJ, Akhtar S (1995) Improved cellular delivery of antisense oligonucleotides using transferrin receptor antibody-oligonucleotide conjugates. Pharm Res 12(10):1548\u20131553. https:\/\/doi.org\/10.1023\/a:1016260110049","journal-title":"Pharm Res"},{"issue":"8","key":"2_CR109","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/hum.2015.070","volume":"26","author":"KE Lundin","year":"2015","unstructured":"Lundin KE, Gissberg O, Smith CIE (2015) Oligonucleotide therapies: the past and the present. Hum Gene Ther 26(8):475\u2013485. https:\/\/doi.org\/10.1089\/hum.2015.070","journal-title":"Hum Gene Ther"}],"container-title":["Methods in Molecular Biology","Gapmers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5476-7_2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:01:53Z","timestamp":1790766113000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5476-7_2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071654750","9781071654767"],"references-count":109,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5476-7_2","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"1 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}